ARX-01 Sufentanil NanoTab PCA System: Phase II data

Data from an open-label, U.S. Phase II trial in 30 patients undergoing unilateral knee replacement surgery showed that 15 ug sublingual ARX-01 met the primary endpoint of no system failures or dosing ...